130 likes | 146 Views
Pancreatic C ancer Case D iscussion. Burçak Erkol, MD Koç University Medical Faculty / Medical Oncology 8th International Gastrointestinal Cancer Conference 09.12.2018. 62 years old female a dmitted to hospital with mid-abdominal pain which increased for 1 month , no other symptoms
E N D
PancreaticCancerCase Discussion Burçak Erkol, MD Koç UniversityMedicalFaculty/MedicalOncology 8th International GastrointestinalCancer Conference 09.12.2018
62 yearsoldfemaleadmittedtohospitalwithmid-abdominalpainwhichincreasedfor1 month, noothersymptoms • Blood biochemistrywas normal • Blood CA19-9 levelwas 917 • Esophagogastroduodenoscopyrevealed a masswhichinvades 2.nd part of duodenum • Abdomen-thoraxCT, MRI and PET CT showedpancreaticmassandperipancreaticlymphnodeswithsuperiormesentericarteryinvasion
ECOG PS: 0 • No physicalexaminationfindings • Hypothyroidism, Hashimotothyroiditis • Exsmoker (20 pack/peryear ) • Levotiron 100mcg
Therewas a 38x30 mm softtissuemass at theuncinateprocess of pancreaswhichinvadesduodenumand SMA morethen 180 degrees, andtouching SMV 180 degrees Itseemsunresectable at this time
Endoscopicultrasoundperformed in August 2017 forbiopsytothe 38x30mm mass at uncinateprocess of pancreas • Pathologicaldiagnosiswasadenocarcinoma of pancreas • ClinicalstageT4N+M0 - III pancreascancer • At GI oncology board wedecidedtogive FOLFIRINOX forthediseaseof thepatient
Thetherapywaswelltoleratedexceptgrade I neutropenia, andgrade I peripheralsensoryneuropathy • After 3 months, 6 cycles of FOLFIRINOX therapy, wediscussthepatient at the GI oncology board again • Her CA19-9 was 33
Thediseasewasstable After 6 cycles -3 months-of FOLFIRINOX wedecidedtocontinuechemo. andadd radiotherapy Borderlineresectable?
After 12 cycles of FOLFIRINOX andfivedays of radiotherapy (5x5 Gy)patient has operatedwithWhipple’sprocedure
Pathologicexaminationrevealedthat • Adenocarcinomagrade I, therewasnomacroscopicmassidentified • Thewidth of regressedtumourwasmesured 1.5 cm in thelargestsection. Therewere 3 carcinomatubule, and 2-3 isolatedcancercells • Therewasacellulermusinallovertheduodenalmuscularispropriaandretroperitonealsurgicalborder
Therewasnolymphatic, perineuralorvenousinvasion • Therewere <%1 alivetumourcells • Mandardgrade II (isolatedtumourcells) • CAP classification: Nearcompleteresponse • No surgicalborderinvasion • No lymphnodeinvolvement LN 49/0, yPT1aN0M0
Wedecidedtomakeactivesurvillance • At December 2018, 7 monthsaftersurgeryshe has stillnolocaleormetastaticevidence of thedisease